Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells

Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate to acetyl-CoA by the enzyme acetyl-CoA synthetase 2 (ACSS2), a key regulator of fatty acid synthesis and protein...

Celý popis

Podrobná bibliografie

Vydáno v:	Frontiers in pharmacology Ročník 15; s. 1394685
Hlavní autoři:	Esquea, Emily M., Ciraku, Lorela, Young, Riley G., Merzy, Jessica, Talarico, Alexandra N., Ahmed, Nusaiba N., Karuppiah, Mangalam, Ramesh, Anna, Chatoff, Adam, Crispim, Claudia V., Rashad, Adel A., Cocklin, Simon, Snyder, Nathaniel W., Beld, Joris, Simone, Nicole L., Reginato, Mauricio J., Dick, Alexej
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 16.05.2024
Témata:	acetate acetyl-CoA brain metastasis breast cancer cancer metabolism Pharmacology acetate computational-aided drug design font: italic formatted: left ACSS2 breast cancer acetyl-CoA brain metastasis cancer metabolism
ISSN:	1663-9812, 1663-9812
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!